Hope Tribune

Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Forecast till 2030

 Breaking News
  • No posts were found

Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Forecast till 2030

August 12
13:52 2020
Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Forecast till 2030

DelveInsight Business Research LLP
DelveInsight’s “Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Forecast to 2030′ report delivers an in-depth understanding of the disease, historical and forecasted Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

CDKL5 Deficiency Disorder (CDD) is a rare developmental epileptic encephalopathy (DEE) caused by mutations in the CDKL5 gene.

CDKL5 Deficiency Disorder Epidemiology Segmentation in 7MM from 2017 to 2030

  • Prevalence of CDKL5 Deficiency Disorder (CDD)
  • Diagnosed Prevalence of CDKL5 Deficiency Disorder (CDD)
  • Gender-Specific Diagnosed Prevalence of CDKL5 Deficiency Disorder (CDD)
  • Clinical Characteristics of CDKL5 Deficiency Disorder (CDD)

CDKL5 Deficiency Disorder Epidemiology Insights

  • The total prevalent population of CDD in 7MM in 2017 was 16,397  
  • The total diagnosed prevalence of CDD in the United States in 2017 – 
    • 208 males
    • 1,315 females
    • Mainly eight types of clinical characteristics of CDD are observed in patients in 2017 :-    
      • 1,234 – Epileptic Spasms
      • 716 – Hypsarrhythmia
      • 1,142 – Cortical Visual Impairment
      • 1,218 – Hand Stereotypies
      • 1,317 – Gastrointestinal Symptoms
      • 1,080 – Constipation
      • 976 – Reflux
      • 1,295 – Sleep Difficulties   

Scope of the Report

  • The Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Report and Model provide an overview of the risk factors and global trends of Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder
  • The report provides the segmentation of the Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder epidemiology

 

Report Highlights

  • Eleven-Year Forecast of CDD
  • 7MM Coverage
  • Prevalence of CDD in 7MM
  • Diagnosed Prevalence of CDD in 7MM
  • Gender-specific Diagnosed Prevalence of CDD
  • Clinical Characteristics of CDD

 

KOL- Views

We interview, KOLs and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

 

Request for sample pages
Table of contents

1. Key Insights 

2. Executive Summary of Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder

3. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder: Disease Background and Overview

3.1. Introduction

3.2. Sign and Symptoms

3.3. Pathophysiology

3.4. Risk Factors

3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

5.1. Epidemiology Key Findings

5.2. Assumptions and Rationale: 7MM

5.3. Epidemiology Scenario: 7MM

5.3.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Scenario in the 7MM (2017- 2030)

5.4. United States Epidemiology

5.4.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Scenario in the United States (2017- 2030)

5.5. EU-5 Country-wise Epidemiology

5.5.1. Germany Epidemiology

5.5.1.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Scenario in Germany (2017- 2030)

5.5.2. France Epidemiology

5.5.2.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Scenario in France (2017- 2030)

5.5.3. Italy Epidemiology

5.5.3.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Scenario in Italy (2017- 2030)

5.5.4. Spain Epidemiology

5.5.4.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Scenario in Spain (2017- 2030)

5.5.5. United Kingdom Epidemiology

5.5.5.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Scenario in the United Kingdom (2017-2030)

5.6. Japan Epidemiology

5.6.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

6.1. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Treatment and Management

6.2. Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Disorder Treatment Algorithm

7. KOL Views

8. Unmet Needs

9.  Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/